ReviewEuropean cardiology2026
Intracardiac Thrombi in Behçet's Disease: Systematic Review of 218 Patients' Clinical Characteristics and Treatments.
Review in European cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behçet's disease (BD) is a rare autoimmune disorder with significant cardiovascular complications, including intracardiac thrombosis (ICT), which can lead to high morbidity and mortality. Methods: We conducted a comprehensive literature search across multiple databases up to December 2024, identifying articles related to BD and ICT. Data were extracted from case reports and cohort studies, focusing on demographics, clinical presentations and treatment outcomes. Results: A total of 218 cases of ICT in BD were analysed, predominantly affecting young males from regions along the historical Silk Road. ICT often presented as the initial manifestation of BD (53.21% of cases), with fever, dyspnoea and haemoptysis as common symptoms. The right heart chambers were most frequently involved. Treatment primarily involved corticosteroids, immunosuppressants and anticoagulants, with a complete resolution rate of 67.22% (n=160). Surgical interventions were associated with high recurrence and mortality rates of 60% and 34.78%, respectively. Conclusion: ICT in BD is a serious complication that requires prompt recognition and management. A multimodal treatment approach combining corticosteroids, immunosuppressants and anticoagulants is recommended to improve outcomes. Surgical intervention carries a higher risk of mortality and morbidity, making it a less preferred treatment option. Clinicians should maintain a high index of suspicion for ICT in BD patients and initiate timely medical therapy to mitigate complications. Further studies are needed to optimise treatment strategies and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.